Does MICRO-TAG cell target engagement system offer an end-to-end solution for drug discovery? #MICROTAG #PrecisionTherapeutics #DrugDiscovery #CellTargetEngagement #DrugTargeting #ChallengingTarget #DrugTarget #BiotechInnovation #TherapeuticDiscovery #BiomedicalInnovation #CellarisBio #DEL #Biotech #Pharma #BiotechAdvancements #PrecisionMedicine #BiotechInnovation
CellarisBio
生物技术研究
San Diego，California 1,263 位关注者
CellarisBio is a drug discovery platform focused on cellular target engagement.
关于我们
CellarisBio is a drug discovery platform focused on cellular target engagement. Our Micro-tag technology enables discovery, validation and optimization of novel therapeutics to challenging drug targets in the physiological environment of the cell. We tackle challenging targets such as transcription factors, membrane proteins and enzymes. We focus therapeutic modalities such as small molecules, Protacs, peptides and antibodies.
- 网站
-
www.cellarisbio.com
CellarisBio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- San Diego，California
- 类型
- 私人持股
- 创立
- 2018
地点
-
主要
获取路线
9276 Scranton Rd
Suite 500
US，California，San Diego，92121
CellarisBio员工
动态
-
What kind of tag does MICRO-TAG cell target engagement system use to track drug targets? #MICROTAG #PrecisionTherapeutics #DrugDiscovery #CellTargetEngagement #DrugTargeting #ChallengingTarget #DrugTarget #BiotechInnovation #TherapeuticDiscovery #BiomedicalInnovation #CellarisBio #DEL #Biotech #Pharma #BiotechAdvancements #PrecisionMedicine #BiotechInnovation
-
Drug : Target in Focus: WRN Helicase is an enzyme that plays a crucial role in maintaining genomic stability by unwinding double-stranded DNA. HRO761 is a potent, selective, allosteric WRN inhibitor that binds at the interface of the D1 and D2 helicase domains, locking WRN in an inactive conformation. It is chameleonic Inhibitor for oncology indications. Developed by Novartis. @Novartis #MICROTAG #PrecisionTherapeutics #DrugDiscovery #CellTargetEngagement #DrugTargeting #ChallengingTarget #DrugTarget #BiotechInnovation #TherapeuticDiscovery #BiomedicalInnovation #CellarisBio #DEL #Biotech #Pharma #BiotechAdvancements
-
-
Does MICRO-TAG cell target engagement system work with DNA-Encoded Libraries (DELs)? Does MICRO-TAG only work with certain kind of DELs? #MICROTAG #PrecisionTherapeutics #DrugDiscovery #CellTargetEngagement #DrugTargeting #ChallengingTarget #DrugTarget #BiotechInnovation #TherapeuticDiscovery #BiomedicalInnovation #CellarisBio #DEL #Biotech #Pharma #BiotechAdvancements #PrecisionMedicine #BiotechInnovation
-
MICRO-TAG cell target engagement technology developed by CellarisBio is essential for modern therapeutic discovery paradigms. #MICROTAG #PrecisionTherapeutics #DrugDiscovery #CellTargetEngagement #DrugTargeting #ChallengingTarget #DrugTarget #BiotechInnovation #TherapeuticDiscovery #BiomedicalInnovation #CellarisBio #DEL #Biotech #Pharma #BiotechAdvancements #PrecisionMedicine #BiotechInnovation
-
-
Drug : Target in Focus: Tyrosine kinase 2 (TYK2) is an enzyme that relays immune signals and plays a critical role in maintaining normal immune responses. TAK-279 (now Zasocitinib) is an oral, allosteric inhibitor of TYK2 that binds to the Janus homology 2 (JH2) pseudokinase domain of TYK2, leading to inhibition of kinase activity and subsequent downstream signaling events. Candidate for best-in-class. Developed by Nimbus Therapeutics & Takeda. @Nimbus Therapeutics @Takeda #MICROTAG #PrecisionTherapeutics #DrugDiscovery #CellTargetEngagement #DrugTargeting #ChallengingTarget #DrugTarget #BiotechInnovation #TherapeuticDiscovery #BiomedicalInnovation #CellarisBio #DEL #Biotech #Pharma #BiotechAdvancements
-
-
MICRO-TAG cell target engagement technology offers the next-gen of cellular on-target drug discovery. Engaging with the complexities of the cellular environment is paramount for drug discovery. #MICROTAG #PrecisionTherapeutics #DrugDiscovery #CellTargetEngagement #DrugTargeting #ChallengingTarget #DrugTarget #BiotechInnovation #TherapeuticDiscovery #BiomedicalInnovation #CellarisBio #DEL #Biotech #Pharma #BiotechAdvancements #PrecisionMedicine #BiotechInnovation
-
-
What is the typical readout from the MICRO-TAG cell target engagement system? #MICROTAG #PrecisionTherapeutics #DrugDiscovery #CellTargetEngagement #DrugTargeting #ChallengingTarget #DrugTarget #BiotechInnovation #TherapeuticDiscovery #BiomedicalInnovation #CellarisBio #DEL #Biotech #Pharma #BiotechAdvancements #PrecisionMedicine #BiotechInnovation
-
We are together in this mission of drug discovery. The promise of better therapeutics drives the mission of CellarisBio forward. #MICROTAG #PrecisionTherapeutics #DrugDiscovery #CellTargetEngagement #DrugTargeting #ChallengingTarget #DrugTarget #BiotechInnovation #TherapeuticDiscovery #BiomedicalInnovation #CellarisBio #DEL #Biotech #Pharma #BiotechAdvancements #PrecisionMedicine #BiotechInnovation
-
-
Drug : Target in Focus: Phosphoinositide 3-kinase alpha (P|3Ka) is a lipid kinase that plays a central role in cell growth and survival. Inavolisib is a PI3Ka isoform-selective inhibitor and monovalent degrader of the mutant p1 10a subunit in PI3Ka. It specifically targets and depletes mutant p 110a in cancer cells with active RTK. Developed by Genentech. @Genentech #MICROTAG #PrecisionTherapeutics #DrugDiscovery #CellTargetEngagement #DrugTargeting #ChallengingTarget #DrugTarget #BiotechInnovation #TherapeuticDiscovery #BiomedicalInnovation #CellarisBio #DEL #Biotech #Pharma #BiotechAdvancements
-